BioSpace News Archive

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial.

ALLITE® Inc. and Xi’an Jiaotong University will collaborate to pave the way for meaningful discoveries in magnesium alloy research.

BioMarker Strategies, LLC, today announced that the National Cancer Institute (NCI) has awarded the Company a Phase II Small Business Innovation Research (SBIR) contract to continue development of its PathMAP® Immunotherapy test to predict clinical response to PD-1/PD-L1 targeted immune checkpoint inhibitors,

Frazier Healthcare Partners announced Bruce Roth, Ph.D., has joined the Frazier Life Sciences team as a Senior Advisor.

Keith Murphy, founder, former CEO and Chairman Emeritus of Organovo, says bioprinting and similar technologies are going strong and still growing

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), announced today that the principal investigator of the Company’s Phase II liver cancer study, Dr. Solomon Stemmer, will deliver a presentation titled “The Safety and Efficacy of Namodenoson in the Second-Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis:

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced receipt of a US$5 million milestone payment, less applicable taxes, from Newsoara BioPharma Co., Ltd. (“Newsoara”) related to a previously announced licensing agreement for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau.

Lirio, a behavior change AI company that uses personalized engagement to improve health outcomes, formed a new research and development lab to develop behavior change AI solutions.

MVP is a national, voluntary research program funded by the VA Office of Research and Development.

This recommendation highlights a specific wellness leadership vacuum in healthcare.